Collaboration aims to uncover biomarkers for prostate cancer

04/23/2013 | GenomeWeb Daily News (free registration)

The Ontario Institute for Cancer Research has agreed to work with Johnson & Johnson unit Janssen on clinical trials that aim to develop new biomarkers for detecting hormone-resistant prostate cancer and predicting therapeutic response. The project will leverage OICR's background in molecular imaging, genomics and circulating tumor cells. As part of the project, researchers will test new imaging agents in tumor evaluation and treatment response assessment.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX